BridgeMD
MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial
EU CTIS ID: 2024-515626-92-00
What this study is testing
To determine the response rate defined as the percentage of patients with CR, PR, SD or lack of recurrence at 6 months after start of antiangiogenic treatment (stratum II, III, V). To determine whether temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt can increase the response rate after 6 months of treatment, compared with etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt (stratum IV).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Stratum I: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) - completed
- Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (raw data of methylation array)
- Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative)
- Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease)
- Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease)
- Histological confirmation of medulloblastoma/ependymoma/ATRT at diagnosis or relapse
You likely can't join if
- Active infection
- Anticipation of the need for major elective surgery during the course of the study treatment
- Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications
- Stratum IV: Prior treatment with temozolomide/irinotecan (can be included in Stratum V)
- Previously non-irradiated patients should be evaluated for radiotherapy
- Non-healing surgical wound
See the full eligibility criteria
- Stratum I: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) - completed
- Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (raw data of methylation array)
- Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative)
- Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease)
- Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease)
- Histological confirmation of medulloblastoma/ependymoma/ATRT at diagnosis or relapse
- Female or male, aged from 0 to <20 years (at time of original diagnosis)
- Participants must have normal organ and bone marrow function (ALT <5x institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal for age, WBC >1000/mm3, platelets > 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol.
- Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used
- Written informed consent of patients and / or parents
- Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease)
- Active infection
- Anticipation of the need for major elective surgery during the course of the study treatment
- Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications
- Stratum IV: Prior treatment with temozolomide/irinotecan (can be included in Stratum V)
- Previously non-irradiated patients should be evaluated for radiotherapy
- Non-healing surgical wound
- A bone fracture that has not satisfactorily healed
- VP- or subduroperitoneal shunt dependency (can be included in Stratum V)
- Pregnancy or breast feeding
- Treatment for current relapse (surgery may be performed before antiangiogenic treatment; patients with sites of disease not irradiated are still eligible for the protocol)
- Known hypersensitivity to any of the drugs in the protocol
- Active peptic ulcer
- Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.